ERBB2 and breast cancer: Jemal et al. evaluated factors contributing to survival disparities in women aged 18–64 years with stage I-III breast cancer; although HER2 status was not reported, excess risk of death in Black compared to White women was reduced from 105.1% to 24.9% when matched for demographics, comorbidities, insurance, tumor characteristics and treatment [48].